Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

June 21, 2010

Study Completion Date

August 12, 2012

Conditions
Breast Cancer
Interventions
BIOLOGICAL

cetuximab

Given IV

DRUG

carboplatin

Given IV

Trial Locations (14)

20007

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C.

20010

Washington Cancer Institute at Washington Hospital Center, Washington D.C.

27607

Rex Cancer Center at Rex Hospital, Raleigh

27710

Duke Comprehensive Cancer Center, Durham

35294

Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham

55905

Mayo Clinic Cancer Center, Rochester

63110

Washington University School of Medicine, St Louis

77030

Baylor University Medical Center - Houston, Houston

94115

UCSF Comprehensive Cancer Center, San Francisco

46202-5289

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Avon Foundation

OTHER

collaborator

National Center for Research Resources (NCRR)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER